WO2015133636A1 - グリモンティア・ホリセー由来リコンビナントコラゲナーゼおよび細胞分離用酵素剤 - Google Patents
グリモンティア・ホリセー由来リコンビナントコラゲナーゼおよび細胞分離用酵素剤 Download PDFInfo
- Publication number
- WO2015133636A1 WO2015133636A1 PCT/JP2015/056748 JP2015056748W WO2015133636A1 WO 2015133636 A1 WO2015133636 A1 WO 2015133636A1 JP 2015056748 W JP2015056748 W JP 2015056748W WO 2015133636 A1 WO2015133636 A1 WO 2015133636A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- collagenase
- recombinant
- grimontia
- derived
- kda
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24007—Interstitial collagenase (3.4.24.7), i.e. matrix metalloprotease 1 or MMP1
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
Definitions
- the present invention relates to a recombinant collagenase derived from Grimontia horise and an enzyme agent for cell separation.
- the pancreas includes exocrine glands that secrete digestive enzymes into the duodenum and pancreatic islets of the endocrine glands.
- a method of isolating and purifying islets that play an important role in regulating blood glucose concentration from the pancreas and transplanting the islets into patients such as type 1 diabetes who are insulin dependent is called islet transplantation.
- Islet is minimally invasive because it can be injected into the body in the manner of infusion, and the physical burden on the patient is low.
- pancreas On the other hand, about 90% of the pancreas is an exocrine gland, and the technology for isolating islets is difficult and its success rate is extremely low.
- a mixture containing the subtypes of collagenase H (ColH) and collagenase G (ColG) derived from Clostridium histolyticum is used in the medical field as an enzyme agent for cell separation in order to separate pancreatic islets from the pancreas.
- ColH collagenase H
- ColG collagenase G
- Non-patent Document 1 Clostridium genus collagenase commonly has a catalytic domain (hereinafter sometimes referred to as CD), a polycystic kidney-like domain (hereinafter sometimes referred to as PKD), It includes three types of collagen binding domains (hereinafter sometimes referred to as CBD), and ColH is a domain structure represented by CD-PKD-PKD-CBD, consisting of one CD, two PKDs, and one CBD.
- CD catalytic domain
- PKD polycystic kidney-like domain
- CBD collagen binding domains
- ColH is a domain structure represented by CD-PKD-PKD-CBD, consisting of one CD, two PKDs, and one CBD.
- ColG is a domain structure represented by CD-PKD-CBD-CBD, consisting of one CD, one PKD, and two CBDs.
- Non-Patent Document 1 states that calcium binds to the N-terminal side of CBD, and that the structure of the N-terminal part of the domain changes due to the removal of calcium, that calcium is important for collagen binding, and that calcium is stable in ColH. Disclose that it contributes to
- Non-patent Document 2 As a collagenase having a high specific activity, there is Grimontia horiseus-derived collagenase (Non-patent Document 2). It is a collagenase with a molecular weight of 84 kDa that includes a prepro region, a catalytic domain, a linker region, and a prepeptidase C-terminal domain (hereinafter also referred to as PPC). As a result of BLAST search, it is found that it has low homology with ColH and ColG. ing.
- Patent Document 1 a method for producing bacmid pCC1BAC-2 containing a gene for all coding regions of Grimontia horrisae collagenase, a Brevibacillus choshinensis recombinant using bacmid pCC1BAC-2, A process for producing Grimontia horrisae collagenase is described.
- Non-patent Document 1 discloses a method for producing Grimontia horrisae-derived collagenase using genetic engineering.
- the specific activity of Grimontia horrisae collagenase sometimes fluctuated. If the specific activity is different for each production lot, it becomes difficult to use different lots with the same protocol. Furthermore, when the activity decreases with time, the amount used may vary, so that the cell yield may vary, or the cells may be burdened by excessive degradation treatment.
- the details of the domain of collagenase derived from Grimontia horrisae have not been elucidated, and the cause of the decrease in specific activity is unknown. Therefore, there is a need for the development of recombinant collagenase derived from collagenase derived from Grimontia horise with stable specific activity.
- the request for cell separation is not limited to islets. Liver, heart, lung, kidney, spleen, adrenal gland, muscle, thyroid gland, salivary gland, parotid gland acinus, glandular tissue such as mammary tissue, bone tissue such as bone, cartilage, endothelial cell, epithelial cell, adipose tissue, etc. May also be used after separating the cells.
- tissue such as mammary tissue, bone tissue such as bone, cartilage, endothelial cell, epithelial cell, adipose tissue, etc.
- the success rate of islet transplantation also depends on the amount of enzyme remaining in the isolated islet, and the transplantation rate decreases if the amount of residual enzyme is large. It is also preferable for other organs and cells that the amount of residual enzyme is small after cell washing. Therefore, a novel collagenase is desired that can be separated quickly from tissue after washing or the collagenase activity when remaining in the washed tissue is reduced, and cell damage can be avoided or reduced.
- an object of the present invention is to provide a novel Grimontia holysei-derived recombinant collagenase having excellent collagenase activity and stable specific activity.
- an object of the present invention is to provide an enzyme agent for cell separation using the thus-obtained novel Grimontia horsei-derived recombinant collagenase.
- the present inventors have examined in detail the gene for collagenase derived from Grimontia horrisae.
- the prepro region is a secretory signal sequence, has a high collagenase activity even when PPC is removed, and connects CD and PPC.
- the inventors have found that when the third amino acid residue from the C-terminal of the linker region sequence is glycine, stable collagen activity can be maintained, and the present invention has been completed.
- the present invention is a recombinant collagenase derived from Grimontia horrisae collagenase comprising a collagenase catalytic domain, a linker region sequence, and a prepeptidase C-terminal domain from the N-terminus to the C-terminus
- the present invention provides a recombinant collagenase derived from Grimontia horisei, characterized in that it does not contain at least the prepeptidase C-terminal domain.
- the present invention also provides the above-described recombinant collagenase derived from Grimontia horsei, wherein the linker region is a linker fragment cleaved by any amide bond.
- the present invention also provides the above-mentioned recombinant collagenase derived from Grimontia horsei, wherein the linker fragment is characterized in that the third amino acid residue from the C-terminal is glycine.
- the linker fragment may be -G 1 -X 1 -Y 1 -G 2 -X 2 -Y 2- (wherein G 1 and G 2 represent glycine, X 1 , Y 1 , X 2 and Y 2 each represent an amino acid residue which may be the same or different.) Is a linker fragment cleaved between Y 1 and G 2 of the amino acid sequence shown by The recombinant collagenase derived from Grimontia horise is provided.
- the linker fragment is a recombinant collagenase in which the C-terminus of the linker fragment is any one of -Gly-Asp-Ser, -Gly-Asn-Glu, -Gly-Glu-Ser, or -Gly-Asn-Thr.
- the above-mentioned recombinant collagenase derived from Grimontia horise is provided.
- the present invention also provides an enzyme agent for cell separation containing the above recombinant collagenase.
- the present invention also includes islets, liver, heart, lung, kidney, spleen, adrenal gland, muscle, thyroid gland, salivary gland, parotid acinar, mammary tissue, bone, cartilage, endothelial cell, epithelial cell, adipose tissue and fibroblast It is used for the separation of one or more cells selected from the group consisting of the above-mentioned enzyme agents for cell separation.
- a recombinant collagenase derived from Grimontia horisei with a stable specific activity is provided.
- the isolated organ is cultured with an enzyme agent for cell degradation containing this recombinant collagenase, cells can be efficiently separated.
- 74 kDa is a 74 kDa collagenase
- 62 kDa is a recombinant 62 kDa collagenase
- 60 kDa is a recombinant 60 kDa collagenase
- M is a marker.
- Example 2 it is a figure which shows the result of having measured the time-dependent change of the specific activity from immediately after refinement
- Example 3 it is a figure which shows a time-dependent change of the specific activity at the time of preserve
- Example 5 It is a figure which shows the result of Example 5 and Comparative Example 1, and performs the pancreatic digestion experiment using recombinant 62 kDa collagenase or collagenase (Liberase) derived from the genus Clostridium, and the number of pancreatic islets and the result of IEQ obtained by decomposition
- FIG. 6A The result of the number of islets is shown in FIG. 6A, and the result of IEQ is shown in FIG. 6B.
- Example 5 it is a figure which shows the optical microscope photograph of the pancreatic islet isolated using the recombinant 62kDa collagenase.
- FIG. 10A shows the results of Example 8 and Comparative Example 2.
- FIG. 10A shows the binding ability of recombinant 62 kDa collagenase to collagen fibers, and FIG.
- FIG. 10B shows the binding of Clostridium genus collagenase (liberase) to collagen fibers. This is a result showing the ability. It is a figure which shows the result of Example 8 and the comparative example 2, and is a figure which shows a mode that the wash
- a first aspect of the present invention is a recombinant collagenase derived from Grimontia horissey-derived collagenase comprising a collagenase catalytic domain, a linker region sequence, and a prepeptidase C-terminal domain from the N-terminus to the C-terminus, ,
- Grimontia horise Collagenase producing microorganisms include the genus Chrostridium sp., Vibrio sp., Bacillus sp., Streptomyces sp. However, the collagenase used in the present invention is derived from the genus Grimontia sp. Grimontia Horise, for example, ATCC No. 33564 and ATCC No. Available as 33565.
- FIG. 1A shows the domain structure of the amino acid sequence of Grimontia horisese-derived collagenase.
- the domain structure represented by “84 kDa collagenase” is a domain structure corresponding to the entire coating sequence of Grimontia horisae collagenase. From N-terminal to C-terminal, amino acid numbers 1 to 87 are prepro regions, amino acid numbers 88 to 615 are catalytic domain regions (CD), amino acid numbers 616 to 687 are linker regions, and amino acid numbers 688 to 749 are PPC domain regions ( PPC). It consists of 767 amino acids and has a molecular weight of 84 kDa.
- the amino acid sequence of collagenase of Grimontia horrissei 1706B strain is shown in SEQ ID NO: 1, and the DNA sequence of all coding regions is shown in SEQ ID NO: 2.
- the prepro region was found to be a secretory signal sequence. However, it is not clear at which stage of translation the secretory signal sequence is released.
- both collagenase having a prepro region and collagenase lacking the prepro region are referred to as Grimontia horrisae-derived collagenase.
- Collagenase derived from Grimontia horisei lacking the prepro region has a molecular weight of 74 kDa. This domain structure is shown in FIG. 1A as “74 kDa collagenase”.
- the recombinant collagenase derived from Grimontia holyse of the present invention is derived from Grimontia holysee.
- the domain structure only needs to include at least PPC.
- the recombinant collagenase is composed of a prepro region, a CD, and a linker region from the N-terminal to the C-terminal, with the sequence after amino acid number 688 deleted. Further, it may be a recombinant collagenase that lacks the prepro region and consists of a CD and a linker region.
- the recombinant collagenase derived from Grimontia horsei of the present invention has reduced collagenase activity after washing and cell damage, as shown in Examples below.
- the linker region of the recombinant collagenase derived from Grimontia horsei of the present invention may be a linker fragment that lacks a part of its amino acid sequence.
- the “linker fragment” in the present invention means a fragment obtained by cleaving at any amide bond in the linker region. For example, in the domain structure shown in the 84 kDa collagenase of FIG. 1A, the domain structure is cleaved by any amide bond in the linker region from 616th to 687th.
- FIG. 1A is an example having a linker fragment consisting of 31 amino acids from 616 to 646, and the “recombinant 60 kDa collagenase” in FIG. 1A consists of 9 amino acids from 616 to 624. This is an example having a linker fragment.
- the third amino acid residue from the C-terminal is preferably glycine.
- Recombinant collagenase in which the third amino acid residue from the C-terminal is glycine is excellent in the stability of collagenase activity as shown in the examples described later.
- the linker region is -G 1 -X 1 -Y 1 -G 2 -X 2 -Y 2- (wherein G 1 and G 2 represent glycine, X 1 , Y 1 , X 2 and Y 2 each represent an amino acid residue which may be the same or different.
- FIG. 1B For convenience, a part of the amino acid sequence of the linker region of “84 kDa collagenase” shown in FIG. 1A is shown in FIG. 1B.
- “60 kDa” indicates the C terminus of “recombinant 60 kDa collagenase”
- “62 kDa” indicates the C terminus of “recombinant 62 kDa collagenase”.
- the C-terminal of the recombinant 60 kDa collagenase is a fragment obtained by cleaving between S and G of the sequence represented by -GDGSAG- in the linker region, and the recombinant 62 kDa collagenase has T and G of the sequence represented by -GNTGLP-. Is cut between the two.
- the third amino acid residue from the C-terminal is glycine.
- the cleavage at -G 1 X 1 Y 1 G 2 X 2 Y 2 -in the linker region is performed between 637 and 638 or between 642 and 643 as shown in FIG. 1B. It may have been cut with
- the C-terminus of the recombinant collagenase of the present invention is the above-mentioned -G 1 -X 1 -Y 1 -G 2 -X 2 -Y 2- (wherein G 1 and G 2 represent glycine, and X 1 , Y 1 , X 2 and Y 2 each represent an amino acid residue which may be the same or different.
- the linker fragment cleaved between Y 1 and G 2 of the amino acid sequence represented by This is because the specific activity of the recombinant collagenase having a linker fragment cleaved between Y 1 and G 2 is stable for a long period of time.
- the C-terminus is preferably any one of -GDS, -GNE, -GES, and -GNT, for example.
- C-terminal will be the sequence.
- the amino acid sequence of the recombinant 60 kDa collagenase of the amino acid sequence of amino acid numbers 88 to 624 is deleted in the prepro region and PPC, and has a predetermined linker fragment.
- SEQ ID NO: 3 and the amino acid sequence of amino acid numbers 88 to 646 The amino acid sequence of the recombinant 62 kDa collagenase is shown in SEQ ID NO: 4.
- a collagenase having the amino acid sequence of amino acid numbers 88 to 767 from which the prepro region has been deleted from the 84 kDa collagenase is referred to as 74 kDa collagenase, and the amino acid sequence is shown in SEQ ID NO: 5.
- the reason why the recombinant collagenase of the present invention is excellent in storage stability is not clear.
- the specific activity and stability of 74 kDa collagenase with PPC and recombinant collagenase without PPC were evaluated, 74 kDa collagenase has higher specific activity, so that PPC itself has collagen binding ability, CD May support the activity of collagenase.
- the recombinant collagenase of the present invention it is presumed that the collagenase activity is stabilized and the separability from the tissue by washing is increased by deleting the PPC that assists the collagenase activity.
- the recombinant collagenase of the present invention may be one in which the linker region is deleted as long as PPC is deleted.
- the transformation DNA for preparing the recombinant collagenase of the present invention encodes at least an amino acid sequence corresponding to CD, more preferably CD and a part of the linker region. Which encodes an amino acid sequence comprising Furthermore, it may have an amino acid sequence corresponding to the prepro region on the N-terminal side.
- the one cleaved between Y 1 and G 2 in the sequence represented by -G 1 X 1 Y 1 G 2 X 2 Y 2- contained in the linker region sequence is preferably used. be able to.
- DNA that does not contain PPC and can be used to produce a recombinant collagenase in which the third from the C-terminus is glycine a DNA encoding the amino acid sequence represented by the following (I) can be used.
- Formula (I): -X X is a polypeptide represented by TEALAKGDSGAGNGEGTGSGNEGGGESGGNT or TEALAKGDS.
- SEQ ID NO: 3 is an amino acid sequence when X is TEALAKGDS
- SEQ ID NO: 4 is an amino acid sequence when X is TEALAKGDSGAGNGEGTGSGNEGGGESGGNT.
- the alphabet used by the said formula shows the following amino acids.
- A Alanine, C: Cysteine, D: Aspartic acid, E: Glutamic acid
- F Phenylalanine
- G Glycine
- H Histidine
- I Isoleucine
- K Lysine
- L Leucine
- M Methionine
- N Asparagine
- P Proline
- Q glutamine
- R arginine
- S serine
- T threonine
- V valine
- W tryptophan
- Y tyrosine.
- a recombinant vector containing DNA encoding the above amino acid sequence is prepared, transformed with the recombinant vector to prepare a host cell having collagenase activity, and the host cell is cultured.
- a gene product having collagenase activity may be produced.
- Such a method for producing a recombinant protein can be carried out using genetic engineering techniques.
- a clone containing a collagenase gene derived from Grimontia horrisae is selected from the genomic library of Grimontia horise, and Nco I is placed on the 5 ′ side of the DNA fragment encoding SEQ ID NO: 3 or SEQ ID NO: 4 using the clone as a template.
- Add a Hind III site to the 3 'side amplify it with Expand High Fidelity PCR System (Roche), treat the amplified fragment with Nco I-Hind III, recover the DNA fragment, plasmid vector, etc.
- Recombinant plasmids are prepared by inserting them into Brevibacillus choshinensis strains, for example, by transforming Brevibacillus choshinensis strain HPD31-SP3.
- a 15 base pair sequence homologous to both ends of the linear expression vector to be inserted into both ends of the DNA fragment encoding SEQ ID NO: 3 or SEQ ID NO: 4 using a clone containing the collagenase gene derived from Grimontia horsei as a template
- the amplified DNA fragment and a linear expression vector were mixed, and then introduced into Brevibacillus choshinensis HPD31-SP3 strain etc.
- the method for collecting and purifying the recombinant collagenase, which is the target substance, from the culture can be performed in accordance with general enzyme collecting and purification means.
- the cells are separated from the culture by centrifugation or filtration, and column separation is performed using ordinary separation means such as organic solvent precipitation, salting out, concentration by ultrafiltration membrane, etc.
- purifying by is mentioned.
- the recombinant collagenase derived from Grimontia horsei of the present invention may produce recombinant collagenase from a host cell previously transformed with a DNA not containing a prepro region, or may be a host cell transformed with a DNA containing a prepro region. Recombinant collagenase may be produced from the prepro region during or after translation.
- the recombinant collagenase obtained by the production method of the present invention can be used in the same manner as a conventional collagenase, and can be used, for example, as an enzyme agent for cell separation.
- an enzyme agent for cell separation In addition to islets, liver, heart, lung, kidney, spleen, adrenal gland, muscle, thyroid gland, salivary gland, parotid gland acinar, mammary gland tissue, bone, cartilage, etc.
- the recombinant collagenase obtained in the present invention has a stable specific activity, it can be suitably used as an enzyme agent for cell separation for isolating pancreatic islets from isolated pancreatic organs. As shown in the examples described later, collagenase activity on the washed tissue is low and cell damage is small.
- the enzyme agent for cell separation used in the present invention may further contain metalloprotease, serine protease, cysteine protease and other components.
- metalloproteases include thermolysin, dispase, Clostridium histolyticum-derived neutral protease, and the like.
- Serine proteases include trypsin and elastase, and cysteine proteases include chymopapain.
- the cell separation enzyme of the present invention is added to the removed organ or animal tissue and cultured for a predetermined time.
- the extract is cultured in the above-described enzyme agent for cell separation and a culture solution to which other components are added, the extracellular matrix and intercellular bonds of the extracted tissue can be separated to isolate the cells.
- the isolated cells may be recovered from the culture solution by filtration or centrifugation.
- pancreatic organs can be used as isolated organs to isolate islets. Since the islets are linked to other tissues in the pancreas by collagen, the islets can be released from other tissues by culturing with collagenase.
- the enzyme agent for cell separation of the present invention is injected from the pancreatic duct of the removed pancreatic organ and cultured for a predetermined time. The culture time may be appropriately selected depending on the state of the tissue used, the amount of recombinant collagenase contained in the enzyme agent for cell separation, and the like. Since islets are lighter than other tissues, they can be purified by density gradient centrifugation after culture.
- pancreatic islets It is not limited to pancreatic islets, but also liver, heart, lung, kidney, spleen, adrenal gland, muscle, thyroid gland, salivary gland, parotid gland, mammary gland tissue such as bone tissue, bone tissue such as bone and cartilage, endothelium It can be suitably used for any cell separation such as cells, epithelial cells, adipose tissue, fibroblasts and the like.
- Example 1 Bacmid pCC1BAC-2 containing the genes for all coating regions of Collagenase derived from Grimontia horissei (Accession number; NITE BP-00739: Date of deposit (original deposit); April 28, 2009: Name of the depository institution; Independent administrative agency product evaluation National Institute of Technology Patent Microorganism Depositary (NPMD): Name of depositary institution; Japan 2920-8, Kazusa Kamashichi, Kisarazu-shi, Chiba Prefecture 2920-8) as a template for the collagenase gene derived from the peptide sequence of SEQ ID NO: 5 An Nco I site was added to the 5 ′ side of the partial sequence (length 2040 bp), and a Hind III site was added to the 3 ′ side, and amplified by the Expand High Fidelity PCR System (Roche).
- NITE BP-00739 Date of deposit (original deposit); April 28, 2009: Name of the depository institution; Independent administrative agency product evaluation National Institute of Technology Patent Microorganism Deposit
- the following primer set was used for the PCR reaction. Of the primer sequences, restriction enzyme sites are underlined. Fwd: AAA CCATGG CTTTCGCTGCGGTTGAACAGTGTGATCT (SEQ ID NO: 6) Rvs: AAA AAGCTT TTACTGACGACACTGGTTAC (SEQ ID NO: 7)
- the DNA fragment recovered by treating the amplified fragment with Nco I-Hind III was inserted into the cloning site of plasmid vector pNY326, and pNY326-Col. 74 was produced. Brevibacillus choshinensis HPD31-SP3 strain was transformed with this recombinant plasmid to produce a recombinant.
- a partial sequence (length) of the collagenase gene derived from the peptide sequence of SEQ ID NO: 3 using, as a template, bacmid pCC1BAC-2 (NITE BP-00739) containing the gene for the entire coating region of Grimontia horrisae collagenase 1611 bp) was isolated using a PCR reaction using the following primer set: Of the primer sequences, sequences homologous to the sequences at both ends of the linear vector are underlined.
- a linear expression vector pNY326 was prepared using a PCR reaction using the following primer set. Among the primer sequences, sequences homologous to the sequences at both ends of the DNA fragment to be inserted are underlined.
- the DNA fragment (1611 bp) encoding the recombinant 60 kDa collagenase of SEQ ID NO: 3 and the linear expression vector pNY326 were mixed at a molar ratio of 2: 1, and then introduced into competent cells by the new Tris-PEG method. Bacillus choshinensis HPD31-SP3 strain was transformed into plasmid pNY326-Col. 60 and recombinants were produced.
- a partial sequence (length: 1677 bp) of the collagenase gene derived from the peptide sequence of SEQ ID NO: 4 was isolated using a PCR reaction using the following primer set. Of the primer sequences, sequences homologous to the sequences at both ends of the linear vector are underlined.
- Rvs CATCCTGTTAAGCTT AGGTATTACCACCAGATTCA (SEQ ID NO: 13)
- a linear expression vector pNY326 was prepared in the same manner as described above, and a plasmid pNY326-Col. Containing a DNA fragment (1677 bp) encoding the recombinant 62 kDa collagenase of SEQ ID NO: 4 was prepared. 62 and recombinants were produced. As described above, three types of Brevibacillus choshinensis recombinants were prepared.
- the HPLC system was performed by anion exchange column chromatography using DEAE-Sepharose. Each culture supernatant was applied to a column to adsorb collagenase, and then 50 mM Bis-Tris HCl buffer (pH 7) was flowed while the NaCl concentration was continuously increased from 0.2 to 1 M to separate and elute collagenase. 4 ml of eluate was collected in the order of elution and fractionated.
- FIG. 74 kDa indicates 74 kDa collagenase
- 62 kDa indicates recombinant 62 kDa collagenase
- 60 kDa indicates recombinant 60 kDa collagenase.
- Example 2 The changes over time in the specific activities of 74 kDa collagenase, recombinant 62 kDa collagenase and recombinant 60 kDa collagenase obtained in Example 1 were measured by the following method. The measurement results are shown in FIG. 74 kDa had an activity of 18,000 (U / mg) immediately after purification, but decreased to 11,500 (U / mg) after 24 hours, and the activity decreased with time. On the other hand, both the recombinant 62 kDa collagenase and the recombinant 60 kDa collagenase transitioned around 12,000 (U / mg) immediately after purification until 24 hours, and the collagenase activity was stable.
- Example 3 The time course of specific activity when the recombinant 62 kDa collagenase obtained in Example 1 was stored at a temperature of 4 ° C. was evaluated. The relative value when the specific activity value on the 0th day is taken as 100% is shown in FIG. As shown in FIG. 4, high specific activity could be stably maintained over 100 days. Recombinant 60 kDa collagenase also showed similar stability.
- Example 4 A pancreatic digestion experiment was performed using the recombinant 62 kDa collagenase obtained in Example 1.
- the pancreas was isolated from a mouse, 0.00625-0.20 mg of recombinant 62 kDa collagenase in 1 ml of HBSS buffer, and 0.012 mg of thermolysin (Roche Applied Science, product name “Liberase C / T”)
- the enzyme solution containing the solution was injected from the pancreatic duct and incubated at 37 ° C. for 15 minutes. Thereafter, the amount of protein in the fraction (decomposed tissue) that passed through a 1 mm mesh and the fraction (non-decomposed tissue) remaining on the mesh was measured.
- Example 5 As in Example 4, pancreatic digestion experiments were performed using the recombinant 62 kDa collagenase obtained in Example 1, the number of islets obtained by decomposition was measured, and IEQ (Islet Equivalent: 1 is a pancreatic islet having a diameter of 150 ⁇ m. The defined international unit of islet volume was evaluated.
- FIG. 6A shows the result of the number of islets due to the difference in the concentration of the recombinant 62 kDa collagenase
- FIG. 6B shows the result of IEQ.
- the optical micrograph of the isolated islet is shown in FIG.
- Example 1 (Comparative Example 1) Instead of the recombinant 62 kDa collagenase obtained in Example 1, a collagenase derived from the genus Clostridium (Roche Applied Science, trade name “Liberase C / T”) was used in the same manner as in Example 5, The number and IEQ were evaluated. The results are also shown in FIGS. 6A and 6B. The recombinant 62 kDa collagenase obtained in Example 1 was able to separate the islets from the pancreatic tissue in the same manner as a conventional commercial product.
- Example 6 The islets obtained in Example 5 were transplanted under the renal capsule of STZ-induced diabetic mice, and blood glucose levels were measured over time.
- the kidney transplanted with islets was removed on the 39th day after transplantation, the blood glucose level increased again.
- FIG. 8A The isolated islet transplanted kidney and a partially enlarged photograph are shown in the upper and lower two stages of the left end of FIG. 8B.
- Example 7 Liver digestion experiments were performed using the recombinant 62 kDa collagenase obtained in Example 1.
- the liver of anesthetized rats was exsanguinated under HBSS buffer perfusion to remove calcium, and then the liver was perfused with recombinant 62 kDa collagenase 0.05 mg / ml and thermolysin 0.01 mg / ml for 10 minutes to add calcium. Later, the liver was removed.
- the isolated liver was ice-cooled, minced with a scalpel, and filtered with a gauze and a strainer. After removing dead cells, the liver cells were collected by centrifugation.
- a phase contrast micrograph of hepatocytes is shown in FIG. When these hepatocytes were cultured for 7 days, the survival rate was 98%.
- Example 8 The ability of the recombinant 62 kDa collagenase obtained in Example 1 to bind to collagen fibers and the collagenase activity remaining in the collagen fibers after washing were evaluated. Place 5 mg of pig skin collagen fiber and 400 ⁇ l of Tris HCl buffer (pH 7.5) containing 0.2 M NaCl and 5 mM CaCl 2 in a spin column containing a filter, and centrifuge at 10,000 rpm for 2 minutes. The collagen fibers were washed with the buffer solution and centrifuged 5 times.
- Tris HCl buffer pH 7.5
- the washing solution is discarded, and the enzyme mixture (recombinant 62 kDa collagenase 0.2 mg / ml, ovalbumin 0.2 mg / ml, orthophenanthroline 4 mM, NaCl 0.2 M, CaCl 100 ⁇ l of Tris HCl buffer (pH 7.5) containing 5 mM of 2 was added, and the mixture was allowed to stand at 4 ° C. for 30 minutes to bind the recombinant 62 kDa collagenase to the collagen fibers. Subsequently, centrifugation was performed at 10,000 rpm for 2 minutes to separate the collagen fibers on the filter and the mixed solution that passed through the filter. A part of this mixture was analyzed by SDS-PAGE.
- collagen fibers bound to collagenase in the spin column were collected in a 2 ml tube, and Tris HCl buffer containing 0.2 M NaCl, 5 mM CaCl 2 , 0.1 mg / ml collagen peptide, 4 mM orthophenanthroline ( pH 7.5) was added, and the mixture was allowed to stand at 4 ° C. for 10 minutes, followed by centrifugation at 10,000 rpm for 2 minutes, and the precipitate was washed with the collagen peptide-containing buffer solution, followed by centrifugation 5 times. . Each of the 5 washing supernatants was analyzed by SDS-PAGE.
- FIG. 11 shows the change over time of the collagen fibers collected at the bottom of the 2 ml tube.
- the supernatant after standing for 20 hours was analyzed by SDS-PAGE. The result of SDS-PAGE is shown in FIG.
- Example 2 The same operation as in Example 8 was carried out except that the same amount of collagenase derived from the genus Clostridium (Roche Applied Science, trade name “Liberase C / T”) was used instead of the recombinant 62 kDa collagenase. The results are shown in FIG. 10B and FIG.
- the liberase band is thin, so that the liberase binds to the collagen fibers, and the washing supernatant when the collagenase-bound collagen fibers are washed with the collagen peptide,
- the band of liberase was thin over washings 1 to 5, and collagenase remained in the collagen fibers even after washing with collagen peptide.
- the same tendency as that of recombinant 62 kDa collagenase was exhibited.
- the enzyme activity of collagenase remaining in the collagen fibers was observed to be different between recombinant 62 kDa collagenase and liberase.
- the higher the collagenase activity of the residual enzyme the faster the amount of collagen fibers decreases.
- the extent to which the amount of collagen fibers is reduced is lower for the recombinant 62 kDa collagenase than for the liberase.
- treatments such as islet isolation cell damage is caused by the residual enzyme. Therefore, it is preferable that the enzyme does not remain after islet isolation or that the collagenase activity is reduced even if the residual enzyme is present.
- the recombinant 62 kDa collagenase and liberase bind to the collagen fiber, and even if this is washed five times with the collagen peptide, a part remains in the collagen fiber.
- the activity of the remaining enzyme was different between the two, and the collagenase activity of the recombinant 62 kDa collagenase was lower than that of Liberase.
- the recombinant 62 kDa collagenase does not have “CBD” that binds to collagen fibers unlike the reberase. Since there is no “CBD”, the binding to collagen fibers is loose, and there may be a difference in collagenase activity due to residual enzyme.
- Example 9 Fluorescently labeled type I collagen (hereinafter referred to as FITC-collagen) of the recombinant 62 kD collagenase obtained in Example 1 and a collagenase derived from the genus Clostridium (Roche Applied Science, trade name “Liberase C / T”) and The degradation activity against the synthetic substrate N- (3 [2-furyl] acryloyl) -Leu-Gly-Pro-Ala (hereinafter referred to as FALGPA) was evaluated.
- FITC-collagen Fluorescently labeled type I collagen
- FITC-collagen uses 50 mM Tris-HCl (pH 7.5, 30 ° C.) buffer containing 0.2 M NaCl, 5 mM CaCl 2 , and FALGPA contains 0.4 M NaCl, 40 mM CaCl 2 . Containing 50 mM Tricine (pH 7.5, 30 ° C.) was used.
- Tris-HCl pH 7.5, 30 ° C.
- FALGPA contains 0.4 M NaCl, 40 mM CaCl 2 .
- Containing 50 mM Tricine pH 7.5, 30 ° C.
- FALGPA was detected and quantified with a microplate reader, and FALGPA degradation activity was evaluated.
- the activity of 1 mg of enzyme decomposing 1 ⁇ mole of the peptide per minute was calculated as a specific activity of 1 U / mg.
- the specific activity obtained is shown in Table 1. It was suggested that the recombinant 62 kD collagenase not only decomposes collagen, but also has excellent degradation activity against the synthetic substrate FALGPA, and therefore has excellent gelatin degradation as well as collagen.
- Example 10 Using the recombinant 62 kDa collagenase obtained in Example 1, the activity against type I, type II, type III, type IV, type V, and type VI collagen was evaluated. 1 ⁇ g / ml collagenase dissolved in 50 mM Tris-HCl buffer (pH 7.5) containing 0.2 M NaCl and 5 mM CaCl 2 was added to 0.5 mg / ml of the above collagen, and 30 ° C. The sample was collected at the start of incubation, after 1 hour, 3 hours, and 5 hours, and analyzed by electrophoresis.
- type II, type III, type IV, type V, and type VI collagen This tendency was similarly observed for type II, type III, type IV, type V, and type VI collagen.
- type IV and type V collagen the band becomes thin when reacted with a recombinant 62 kDa collagenase for 3 hours or 5 hours, whereas the band does not disappear with reberase.
- the type VI collagen has a thin band when reacted with a recombinant 62 kDa collagenase for 72 hours, whereas the band does not disappear with reberase. It was suggested that the recombinant 62 kDa collagenase can also degrade collagen that is not easily degraded by liberase.
- a recombinant collagenase having a stable specific activity and an enzyme agent for cell separation containing the recombinant collagenase are provided and useful.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Cell Biology (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
少なくとも、前記プレペプチダーゼC末端ドメインを含まないことを特徴とする、グリモンティア・ホリセー由来リコンビナントコラゲナーゼを提供するものである。
コラゲナーゼを産生する微生物としてクロストリジウム属(Chrostridium sp.)、ビブリオ属(Vibrio sp.)、バチルス属(Bacillus sp.)、ストレプトマイセス属(Streptomyces sp.)などが知られているが、本発明で使用するコラゲナーゼは、グリモンティア属(Grimontia sp.)に由来する。なお、グリモンティア・ホリセーは、例えばATCC No.33564やATCC No.33565として入手することができる。
グリモンティア・ホリセー由来コラゲナーゼのアミノ酸配列のドメイン構造を図1Aに示す。「84kDaコラゲナーゼ」で示すドメイン構造は、グリモンティア・ホリセー由来コラゲナーゼの全コーティング配列に対応するドメイン構造である。N末端からC末端に向かって、アミノ酸番号1~87がプレプロ領域、アミノ酸番号88~615が触媒ドメイン領域(CD)、アミノ酸番号616~687がリンカー領域、アミノ酸番号688~749がPPCドメイン領域(PPC)である。767個のアミノ酸で構成され、分子量は84kDaである。グリモンティア・ホリセー由来コラゲナーゼの一例として、グリモンティア・ホリセー1706B株のコラゲナーゼのアミノ酸配列を配列番号1に、全コーディング領域のDNA配列を配列番号2に示す。なお、前記プレプロ領域は、分泌シグナル配列であることが判明した。ただし、翻訳のいずれの段階で分泌シグナル配列が離脱するかは明確ではない。本発明では、プレプロ領域を有するコラゲナーゼおよびプレプロ領域を欠失したコラゲナーゼの双方を、グリモンティア・ホリセー由来コラゲナーゼとする。プレプロ領域を欠失したグリモンティア・ホリセー由来コラゲナーゼの分子量は74kDaである。このドメイン構造を、図1Aに、「74kDaコラゲナーゼ」として示す。
本発明のグリモンティア・ホリセー由来リコンビナントコラゲナーゼは、グリモンティア・ホリセーに由来する。そのドメイン構造は、少なくともPPCを含まないものであればよい。例えば、前記図1Aの84kDaコラゲナーゼに示すドメイン構造において、アミノ酸番号688以降の配列が欠失され、N末端からC末端に向かって、プレプロ領域、CD、リンカー領域で構成されるリコンビナントコラゲナーゼである。更にプレプロ領域を欠失し、CDとリンカー領域とからなるリコンビナントコラゲナーゼであってもよい。後記する実施例に示すように、PPCを欠失しても高いコラゲナーゼ活性を発揮し、かつコラゲナーゼ活性が安定することが判明した。更に、本発明のグリモンティア・ホリセー由来リコンビナントコラゲナーゼは、後記実施例に示すように、洗浄後のコラゲナーゼ活性が低減され、細胞障害が低減される。
本発明のリコンビナントコラゲナーゼを調製する際の形質転換用DNAとしては、少なくともCDに対応するアミノ酸配列をコードするものであり、より好ましくはCDとリンカー領域の一部とを含むアミノ酸配列をコードするものである。更に、N末端側に、プレプロ領域に対応するアミノ酸配列を有するものであってもよい。リンカー領域のC末端は、リンカー領域配列に含まれる-G1X1Y1G2X2Y2-で示される配列のY1とG2との間で切断されたものを好適に使用することができる。PPCを含まず、C末端から3番目がグリシンとなるリコンビナントコラゲナーゼを作製するために使用し得るDNAとしては、下記(I)で示されるアミノ酸配列をコードするものを使用することできる。
AVEQCDLSQFQTTSSNQLMAAIRQQGASCVNALFSADTGVQEAAFSSNHMYNVAQYTRTLAQQYAGGGSDELEALYLYLRAGYYAEFYNSNITFLSWVTPAVKGAVDAFVQNAHFYDNGDAHGKVLNEVIITMDSAGLQHAYLDVVTQWLTRWNAQYAEHWYMRNAVNGVFTLLFGGQWNNQYTSLIGEQTALVTALQAFALDRTKVNSPTEFMAANAARELGRLARYTDATIAPKVTEGLTAIFGQYPSYGDGDAIWLGAADTASYYADCSQFNICGFEDALRDAALNQTFICSDTIKIRSQDMSQAQHLAACDKMAYEESFFHTTLETGNQPVADDHNTQLQVNIFNSDTDYGKYAGPIFGIDTNNGGMYLEGNPANVGNIPNFIAYEASYANPDHFVWNLEHEYVHYLDGRFNMYGDFGTPTELVVWWSEGVAEYVSRVNDNPQAIATIQDGSTYTLAQVFDTTYDGFDVDRIYRWGYLAVRFMFERHPDEVQRMLSATRQGRWAEYKAIISGWANQYQSEFAQW-X
ただし、Xは、TEALAKGDSGAGNGEGTGSGNEGGGESGGNT、またはTEALAKGDSで示されるポリペプチドである。配列番号3は、XがTEALAKGDSである場合のアミノ酸配列であり、配列番号4は、XがTEALAKGDSGAGNGEGTGSGNEGGGESGGNTである場合のアミノ酸配列である。なお、上記式で使用されるアルファベットは、以下のアミノ酸を示す。A:アラニン、C:システイン、D:アスパラギン酸、E:グルタミン酸 F:フェニルアラニン、G:グリシン、H:ヒスチジン、I:イソロイシン、K:リシン、L:ロイシン、M:メチオニン、N:アスパラギン、P:プロリン、Q:グルタミン、R:アルギニン、S:セリン、T:スレオニン、V:バリン、W:トリプトファン、Y:チロシン。
本発明の製造方法で得たリコンビナントコラゲナーゼは、従来のコラゲナーゼと同様に使用することができ、例えば細胞分離用酵素剤として使用することができる。摘出臓器から細胞を分離する対象として、膵島、肝臓、心臓、肺、腎臓、脾臓、副腎、筋肉の他、甲状腺、唾液腺、耳下腺腺房、乳腺組織などの腺組織、骨、軟骨などの骨組織、内皮細胞、上皮細胞、脂肪組織、繊維芽細胞などがある。摘出組織に限定されず、コラーゲン培地内で培養した培養細胞の分離にも好適である。特に本発明で得たリコンビナントコラゲナーゼは、比活性が安定性しているため、摘出した膵臓臓器から膵島を単離するための細胞分離用酵素剤として好適に使用することができる。後記する実施例に示すように、洗浄組織に対するコラゲナーゼ活性が低く、細胞損傷が少ない。
摘出した臓器や動物組織に本発明の細胞分離用酵素剤を添加して所定時間培養する。摘出物を上記細胞分離用酵素剤や、更に他の成分を添加した培養液で培養すると、前記摘出組織の細胞外マトリックスや細胞間結合を分離し、細胞を単離することができる。組織から単離された細胞が培養液中に浮遊する場合は、培養液からろ過や遠心などで単離細胞を回収すればよい。
グリモンティア・ホリセー由来コラゲナーゼの全コーティング領域の遺伝子を含むバクミドpCC1BAC-2(受託番号;NITE BP-00739:寄託日(原寄託);2009年4月28:寄託機関の名称;独立行政法人製品評価技術基盤機構特許微生物寄託センター(NPMD):寄託機関のあて名;日本国2920818千葉県木更津市かずさ鎌足2-5-8)を鋳型として、配列番号5のペプチド配列から誘導された当該コラゲナーゼ遺伝子の部分配列(長さ2040bp)の5’側にNco Iサイトを、3’側にHind IIIサイトを付加し、Expand High Fidelity PCR System(Roche)により増幅した。PCR反応には、下記プライマーセットを使用した。プライマーの配列のうち、制限酵素サイトを下線で示す。
Fwd:AAACCATGGCTTTCGCTGCGGTTGAACAGTGTGATCT(配列番号6)
Rvs: AAAAAGCTTTTACTGACGACACTGGTTAC(配列番号7)
増幅された断片をNco I-Hind IIIで処理して回収した当該DNA断片を、プラスミドベクターpNY326のクローニングサイトに挿入して、pNY326-Col.74を作製した。この組換えプラスミドでブレビバチルス・チョウシネンシスHPD31-SP3株を形質転換して、組換え体を作製した。
プライマー:
Fwd:CCCATGGCTTTCGCTGCGGTTGAACAGTGTGATCT(配列番号8)
Rvs:CATCCTGTTAAGCTTACTGTCGCCCTTCGCCAGC(配列番号9)
プライマー:
Fwd: AAGCTTAACAGGATGCGGGG(配列番号10)
Rvs: AGCGAAAGCCATGGGAGCAA(配列番号11)
プライマー:
Fwd:CCCATGGCTTTCGCTGCGGTTGAACAGTGTGATCT(配列番号12)
Rvs:CATCCTGTTAAGCTTAGGTATTACCACCAGATTCA(配列番号13)
実施例1で得た74kDaコラゲナーゼ、リコンビナント62kDaコラゲナーゼおよびリコンビナント60kDaコラゲナーゼの比活性の経時変化を下記方法で測定した。測定結果を図3に示す。74kDaは、精製直後に18,000(U/mg)の活性であったが24時間後には11,500(U/mg)に低減し、活性が経時的に低下した。これに対し、リコンビナント62kDaコラゲナーゼおよびリコンビナント60kDaコラゲナーゼは、精製直後から24時間時に至るまで、いずれも12,000(U/mg)前後で推移し、コラゲナーゼ活性が安定していた。
実施例1で得たリコンビナント62kDaコラゲナーゼを、温度4℃で保存した際の比活性の経時変化を評価した。0日目の比活性値を100%とした時の相対値を図4に示す。図4に示すように、100日間に亘り、高い比活性を安定に維持することができた。なお、リコンビナント60kDaコラゲナーゼも同様の安定性を示した。
実施例1で得たリコンビナント62kDaコラゲナーゼを用いて膵臓消化実験を行った。マウスより膵臓を単離し、HBSSバッファー1mlに、リコンビナント62kDaコラゲナーゼを0.00625~0.20mgと、サーモリシン(ロシュアプライドサイエンス社製、商品名「リベラーゼC/T」の内包品)0.012mgとを含む酵素液を膵管より注入し、37℃で15分間インキュベートした。その後、目開き1mmメッシュを通過した画分(分解組織)と、メッシュ上に残った画分(非分解組織)のタンパク量を測定した。酵素液に含まれるリコンビナント62kDaコラゲナーゼの濃度に依存して、分解組織量が増加し、それに伴い非分解組織量が低減した。結果を図5に示す。図5に示すように、リコンビナント62kDaコラゲナーゼの濃度が0.05mg/mlで反応はプラトーに達した。
実施例4と同様に、実施例1で得たリコンビナント62kDaコラゲナーゼを用いて膵臓消化実験を行い、分解して得た膵島の個数を測定し、IEQ(Islet Equivalent:直径が150μmの膵島を1と規定する、膵島の体積を示す国際単位)を評価した。リコンビナント62kDaコラゲナーゼの濃度の相違による膵島の個数の結果を図6Aに、IEQの結果を図6Bに示す。また、単離された膵島の光学顕微鏡写真を図7に示す。
実施例1で得たリコンビナント62kDaコラゲナーゼに代えてクロストリジウム属由来のコラゲナーゼ(ロシュアプライドサイエンス社製、商品名「リベラーゼC/T」)を使用した以外は、実施例5と同様に操作し、膵島の個数およびIEQを評価した。結果を図6A、図6Bに併せて記載する。実施例1で得たリコンビナント62kDaコラゲナーゼは、従来の市販品と同様に、膵臓組織から膵島を分離することができた。
実施例5で得た膵島を、STZ誘導糖尿病マウスの腎皮膜下に移植し、経時的に血糖値を測定した。膵島を移植しなかったコントロール群(n=3:STZ-1、STZ-2、STZ-3)では、高血糖値を示したのに対し、膵島移植群(n=5:STZ/islet-1~STZ/islet-5)では、移植後すぐに血糖値が正常レベルにまで低下した。移植後39日目に膵島を移植した腎臓を摘出すると、血糖値が再び上昇した。結果を図8Aに示す。摘出した膵島移植腎とその部分拡大写真を図8Bの左端の上下2段に示す。また、摘出した膵島移植腎のヘマトキシリン・エオジン染色(H&E染色)を行ったところ腎皮膜下に膵島が確認され、さらには抗インシュリン抗体で膵島が染色された(図8B)。これらは、実施例1で得たリコンビナント62kDaコラゲナーゼにより、膵島機能が保持された膵島が単離できたことを示すものである。
実施例1で得たリコンビナント62kDaコラゲナーゼを用いて肝臓消化実験を行った。麻酔したラットの肝臓をHBSSバッファー潅流下に脱血してカルシウムを除去し、次いで肝臓内にリコンビナント62kDaコラゲナーゼ0.05mg/mlとサーモリシン0.01mg/mlとを10分間潅流してカルシウムを添加した後、肝臓を摘出した。摘出肝臓を氷冷し、メスで細切し、ガーゼおよびストレイナーでろ過した。死細胞を除去した後に肝臓細胞を遠心回収した。肝細胞の位相差顕微鏡写真を図9に示す。この肝細胞を7日間培養したところ、生存率は98%であった。
実施例1で得たリコンビナント62kDaコラゲナーゼのコラーゲン線維への結合能と、洗浄後コラーゲン線維に残留するコラゲナーゼ活性を評価した。
豚皮コラーゲン線維5mgと400μlの0.2MのNaCl、5mMのCaCl2を含むトリスHCl緩衝液(pH7.5)とをフィルターを内蔵するスピンカラムに入れ、10,000rpmで2分間の遠心を行い、コラーゲン線維を前記緩衝液で洗浄して全5回の遠心分離を行った。
洗浄液を廃棄し、前記スピンカラムのフィルター上のコラーゲン線維に酵素混合液(リコンビナント62kDaコラゲナーゼを0.2mg/ml、オボアルブミンを0.2mg/ml、オルトフェナントロリンを4mM、NaClを0.2M、CaCl2を5mM含むトリスHCl緩衝液(pH7.5))100μlを添加し、4℃で30分静置し、コラーゲン線維にリコンビナント62kDaコラゲナーゼを結合させた。
次いで、10,000rpmで2分間の遠心分離を行い、前記フィルター上のコラーゲン線維とフィルターを通過した混合液とに分離した。この混合液の一部を、SDS-PAGEで分析した。なお、比較のために豚皮コラーゲン線維を添加せず、上記と同様に処理して得た混合液も、SDS-PAGEで分析した。結果を図10Aの「混合液/コラーゲン線維「-」、「+」」で示す。リコンビナント62kDaコラゲナーゼのバンドは、「+」で薄く「-」で濃くなった。リコンビナント62kDaコラゲナーゼは、コラーゲン線維と混合すると、コラーゲン線維に結合することが示された。なお、図10においてMはマーカーを示す。
リコンビナント62kDaコラゲナーゼに代えて同量のクロストリジウム属由来のコラゲナーゼ(ロシュアプライドサイエンス社製、商品名「リベラーゼC/T」)を用いた以外は実施例8と同様に操作した。結果を図10Bおよび図11に示す。
実施例1で得たリコンビナント62kDコラゲナーゼおよびクロストリジウム属由来のコラゲナーゼ(ロシュアプライドサイエンス社製、商品名「リベラーゼC/T」)の、蛍光標識したI型コラーゲン(以下、FITC-コラーゲンと称す。)および合成基質N-(3[2-furyl]acryloyl)-Leu-Gly-Pro-Ala(以下、FALGPAと称す。)に対する分解活性を評価した。
FITC-コラーゲンは、0.2MのNaCl、5mMのCaCl2を含む50mMのTris-HCl(pH7.5、30℃)緩衝液を使用し、FALGPAには0.4MのNaCl、40mMのCaCl2を含む50mM トリシン(pH7.5、30℃)を使用した。FITC-コラーゲンを基質とする場合には上記コラゲナーゼを0.5μg添加し、FALGPAを基質とする場合には、リコンビナント62kDコラゲナーゼを1.0μg、またはリベラーゼC/Tを2.5μg添加した。マイクロプレートリーダーにてFALGPAを検出および定量し、FALGPA分解活性を評価した。反応系1mlにおいて、1mgの酵素が1分あたり1μmoleの前記ペプチドを分解する活性を比活性1U/mgとし算出し、得られた比活性を表1に示した。リコンビナント62kDコラゲナーゼは、コラーゲンを分解できるだけでなく、合成基質FALGPAに対する分解活性に優れるため、コラーゲンのみならずゼラチン分解性にも優れることが示唆された。
実施例1で得たリコンビナント62kDaコラゲナーゼを用いて、I型、II型、III型、IV型、V型、およびVI型コラーゲンに対する活性を評価した。0.5mg/mlの上記コラーゲンに、0.2MのNaClと5mMのCaCl2とを含有する50mMのTris-HCl緩衝液(pH7.5)に溶解した1μg/mlのコラゲナーゼを添加し、30℃でインキュベートし、インキュベート開始時、1時間後、3時間後、5時間後にサンプルを分取し、電気泳動で分析した。また、比較のため、クロストリジウム属由来のコラゲナーゼ(ロシュアプライドサイエンス社製、商品名「リベラーゼC/T」)を用いて同様の操作を行った。結果を図12に示す。なお、図12において、62kDaは、リコンビナント62kDaコラゲナーゼを使用したカラムを、リベラーゼは、クロストリジウム属由来のコラゲナーゼを用いたカラムを示す。
I型コラーゲンでは、α1(I)およびα2(I)の3時間後、5時間後のバンドの消失の程度から、リコンビナント62kDaコラゲナーゼの方がリベラーゼよりも迅速にI型コラーゲンを分解していると推定された。この傾向は、II型、III型、IV型、V型、VI型コラーゲンでも同様に観察された。特にIV型およびV型コラーゲンは、リコンビナント62kDaコラゲナーゼを用いて3時間、または5時間反応させるとバンドが薄くなるのに対し、リベラーゼではバンドが消失していない。VI型コラーゲンは、リコンビナント62kDaコラゲナーゼを用いて72時間反応させるとバンドが薄くなるのに対し、リベラーゼではバンドが消失していない。リコンビナント62kDaコラゲナーゼは、リベラーゼで分解が容易でないコラーゲンも分解できる可能性が示唆された。
Claims (7)
- N末端からC末端に向かって、コラゲナーゼ触媒ドメインと、リンカー領域配列と、プレペプチダーゼC末端ドメインとを含むグリモンティア・ホリセー由来コラゲナーゼに由来するリコンビナントコラゲナーゼであって、
少なくとも、前記プレペプチダーゼC末端ドメインを含まないことを特徴とする、グリモンティア・ホリセー由来リコンビナントコラゲナーゼ。 - 前記リンカー領域は、いずれかのアミド結合で切断されたリンカー断片であることを特徴とする、請求項1記載のグリモンティア・ホリセー由来リコンビナントコラゲナーゼ。
- 前記リンカー断片は、C末端から3番目のアミノ酸残基がグリシンであることを特徴とする、請求項2記載のグリモンティア・ホリセー由来リコンビナントコラゲナーゼ。
- 前記リンカー断片は、前記リンカー領域に含まれる-G1-X1-Y1-G2-X2-Y2-(式中、G1とG2とはグリシンを示し、X1、Y1、X2およびY2は、それぞれ同一でも異なっていてもよいアミノ酸残基を示す。)で示すアミノ酸配列のY1とG2との間で切断されたリンカー断片であることを特徴とする、請求項2記載のグリモンティア・ホリセー由来リコンビナントコラゲナーゼ。
- 前記リンカー断片のC末端は、-Gly-Asp-Ser、-Gly-Asn-Glu、-Gly-Glu-Ser、または-Gly-Asn-Thrのいずれかであるリコンビナントコラゲナーゼである、請求項2記載のグリモンティア・ホリセー由来リコンビナントコラゲナーゼ。
- 請求項1~5のいずれかに記載のリコンビナントコラゲナーゼを含む、細胞分離用酵素剤。
- 膵島、肝臓、心臓、肺、腎臓、脾臓、副腎、筋肉、甲状腺、唾液腺、耳下腺腺房、乳腺組織、骨、軟骨、内皮細胞、上皮細胞、脂肪組織および繊維芽細胞からなる群から選択される1以上の細胞の分離に使用されることを特徴とする、請求項6記載の細胞分離用酵素剤。
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2016506205A JP6661072B2 (ja) | 2014-03-06 | 2015-03-06 | 細胞分離用酵素剤 |
CN201580012276.4A CN106164269A (zh) | 2014-03-06 | 2015-03-06 | 源于霍氏格里蒙菌的重组胶原酶和细胞分离用酶剂 |
KR1020167026742A KR20160131037A (ko) | 2014-03-06 | 2015-03-06 | 그리몬티아·홀리새 유래 재조합 콜라게나아제 및 세포 분리용 효소제 |
EP15757886.5A EP3115455A4 (en) | 2014-03-06 | 2015-03-06 | Grimontia-hollisae-derived recombinant collagenase and enzyme agent for cell separation |
US15/123,986 US10047353B2 (en) | 2014-03-06 | 2015-03-06 | Grimonitia-hollisae-derived recombinant collagenase and enzyme agent for cell and tissue dissociation |
CA2941738A CA2941738C (en) | 2014-03-06 | 2015-03-06 | Grimontia-hollisae-derived recombinant collagenase and enzyme agent for cell and tissue dissociation |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014-044205 | 2014-03-06 | ||
JP2014044205 | 2014-03-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2015133636A1 true WO2015133636A1 (ja) | 2015-09-11 |
Family
ID=54055433
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2015/056748 WO2015133636A1 (ja) | 2014-03-06 | 2015-03-06 | グリモンティア・ホリセー由来リコンビナントコラゲナーゼおよび細胞分離用酵素剤 |
Country Status (7)
Country | Link |
---|---|
US (1) | US10047353B2 (ja) |
EP (1) | EP3115455A4 (ja) |
JP (1) | JP6661072B2 (ja) |
KR (1) | KR20160131037A (ja) |
CN (1) | CN106164269A (ja) |
CA (1) | CA2941738C (ja) |
WO (1) | WO2015133636A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2015211655A (ja) * | 2014-05-02 | 2015-11-26 | 株式会社ニッピ | ペプチド組成物の調製方法、細胞培養方法、およびペプチド組成物 |
JP2019083741A (ja) * | 2017-11-07 | 2019-06-06 | 株式会社ニッピ | コラーゲン結合材、その製造方法、ドラッグデリバリーシステム、および担持体 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0870853A (ja) * | 1994-09-05 | 1996-03-19 | Nippi:Kk | ビブリオ属に属する新規な微生物ならびに当該微生物から生産される新規なコラーゲン分解酵素およびその利用 |
JP2010263880A (ja) * | 2009-04-16 | 2010-11-25 | Nippi:Kk | 微生物由来の新規コラゲナーゼ遺伝子 |
JP2011024439A (ja) * | 2009-07-22 | 2011-02-10 | Tokyo Metropolitan Government | サンプル核酸の調製方法 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3022984B2 (ja) * | 1989-11-28 | 2000-03-21 | サントリー株式会社 | 細菌コラゲナーゼ遺伝子 |
EP0941311B1 (de) * | 1996-11-19 | 2004-07-28 | Boehringer Mannheim Gmbh | Rekombinante collagenase typ i aus clostridium histolyticum und ihre verwendung zur isolierung von zellen und zellverbänden |
US20100159564A1 (en) * | 2007-11-30 | 2010-06-24 | Dwulet Francis E | Protease resistant recombinant bacterial collagenases |
-
2015
- 2015-03-06 WO PCT/JP2015/056748 patent/WO2015133636A1/ja active Application Filing
- 2015-03-06 JP JP2016506205A patent/JP6661072B2/ja active Active
- 2015-03-06 EP EP15757886.5A patent/EP3115455A4/en not_active Withdrawn
- 2015-03-06 CN CN201580012276.4A patent/CN106164269A/zh active Pending
- 2015-03-06 CA CA2941738A patent/CA2941738C/en active Active
- 2015-03-06 KR KR1020167026742A patent/KR20160131037A/ko not_active Application Discontinuation
- 2015-03-06 US US15/123,986 patent/US10047353B2/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0870853A (ja) * | 1994-09-05 | 1996-03-19 | Nippi:Kk | ビブリオ属に属する新規な微生物ならびに当該微生物から生産される新規なコラーゲン分解酵素およびその利用 |
JP2010263880A (ja) * | 2009-04-16 | 2010-11-25 | Nippi:Kk | 微生物由来の新規コラゲナーゼ遺伝子 |
JP2011024439A (ja) * | 2009-07-22 | 2011-02-10 | Tokyo Metropolitan Government | サンプル核酸の調製方法 |
Non-Patent Citations (4)
Title |
---|
KATSUMASA IIJIMA ET AL.: "Rinsho Suito Bunri no Tameno Grimontia hollisae ni Yurai suru Shinki Recombinant Collagenase Seizai no Kaihatsu", THE 41ST ANNUAL CONGRESS OF JAPANESE PANCREAS AND ISLET TRANSPLANTATION ASSOCIATION PROGRAM SHOROKUSHU, February 2014 (2014-02-01), pages 101, O-53, XP008184914 * |
KOKI SUZUKI: "Properties of collagenase preparated from the culture of Vibrio hollisae 1706B strain", HIKAKU KAGAKU, vol. 45, no. 4, 2000, pages 272 - 283, XP008185217 * |
See also references of EP3115455A4 * |
TERAMURA N. ET AL.: "Cloning of a novel collagenase gene from the gram-negative bacterium Grimontia (Vibrio) hollisae 1706B and its efficient expression in Brevibacillus choshinensis", J. BACTERIOL., vol. 193, no. 12, 2011, pages 3049 - 3056, XP055223026 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2015211655A (ja) * | 2014-05-02 | 2015-11-26 | 株式会社ニッピ | ペプチド組成物の調製方法、細胞培養方法、およびペプチド組成物 |
JP2019083741A (ja) * | 2017-11-07 | 2019-06-06 | 株式会社ニッピ | コラーゲン結合材、その製造方法、ドラッグデリバリーシステム、および担持体 |
JP7045166B2 (ja) | 2017-11-07 | 2022-03-31 | 株式会社ニッピ | コラーゲン結合材、その製造方法、ドラッグデリバリーシステム、および担持体 |
Also Published As
Publication number | Publication date |
---|---|
US20170218352A1 (en) | 2017-08-03 |
CN106164269A (zh) | 2016-11-23 |
EP3115455A1 (en) | 2017-01-11 |
CA2941738A1 (en) | 2015-09-11 |
EP3115455A4 (en) | 2017-09-13 |
CA2941738C (en) | 2023-02-28 |
KR20160131037A (ko) | 2016-11-15 |
US10047353B2 (en) | 2018-08-14 |
JPWO2015133636A1 (ja) | 2017-04-27 |
JP6661072B2 (ja) | 2020-03-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5698536B2 (ja) | アフィニティタグが結合した融合コラゲナーゼおよびその製造法 | |
JP2015226547A (ja) | 融合タンパク質の自己タンパク質分解切断による組換えタンパク質の産生 | |
JP2001510331A (ja) | クロストリジウム・ヒストリチカム由来の組換えコラゲナーゼタイプ▲i▼および細胞と細胞群の単離へのその使用 | |
US11542489B2 (en) | Expression vector encoding a Paenibacillus polymxa neutral protease | |
US20100159564A1 (en) | Protease resistant recombinant bacterial collagenases | |
JP6661072B2 (ja) | 細胞分離用酵素剤 | |
CN109021071B (zh) | 肽及其制备方法和用途 | |
JP2010263880A (ja) | 微生物由来の新規コラゲナーゼ遺伝子 | |
EA005586B1 (ru) | Гибридный белок проинсулина и способ получения из него рекомбинантного инсулина | |
CN116478969A (zh) | 胶原酶突变体、促进重组胶原酶分泌表达的方法及其应用 | |
CN102559645B (zh) | 一种人阴离子胰蛋白酶突变体 | |
JP2002541793A (ja) | 膵臓プロカルボキシペプチダーゼb、そのアイソフォームおよび突然変異タンパク質の製造ならびにそれらの使用 | |
JP2938352B2 (ja) | 組換え人マトリライシンの製造方法 | |
JPS61192288A (ja) | ヒトエラスタ−ゼ2の生物工学的製造 | |
JP4564791B2 (ja) | スタテリン融合タンパク質 | |
JP2020070293A (ja) | 機能性ペプチドの絹糸への結合法 | |
WO2023030562A1 (en) | Genetically modified bacterial strain e. coli producing clostripain peptidase | |
JP2019083741A (ja) | コラーゲン結合材、その製造方法、ドラッグデリバリーシステム、および担持体 | |
WO2006137209A1 (ja) | Dna、ベクター、形質転換体、及びapaタンパク質の製造方法 | |
PT107276B (pt) | Método para produção de colagenase recombinante para digestão de colagénios | |
MXPA01009979A (en) | Production of pancreatic procarboxy-peptidase b, isoforms and muteins thereof, and their use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15757886 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2941738 Country of ref document: CA Ref document number: 2016506205 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15123986 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 20167026742 Country of ref document: KR Kind code of ref document: A |
|
REEP | Request for entry into the european phase |
Ref document number: 2015757886 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2015757886 Country of ref document: EP |